Can old drugs stop Radiation's lingering damage? new trial aims to find out
NCT ID NCT06912763
First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 4 times
Summary
This phase 2 trial tests several medications—including pravastatin, pentoxifylline, and others—to see if they can treat or prevent lymphedema and fibrosis caused by radiation therapy in head and neck cancer survivors. About 250 participants who have finished radiation at least 6 months ago and have swelling or tissue hardening will be randomly assigned to one of the drugs or standard care. The goal is to find the safest and most effective option to ease these long-term side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Pravastatin, Pentoxifylline, Ketoprofen, Pirfenidone, Tocopherol
- What this could lead to
- If successful, this could identify an effective drug combination to reverse or prevent painful swelling and tissue hardening after radiation, improving quality of life for head and neck cancer survivors.
- What could go wrong
- This is a mid-stage trial with multiple drugs, so it is unclear which, if any, will work. Side effects like muscle pain or liver issues are possible, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 250 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2025
- Expected to finish
-
Jul 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Eligibility Criteria Eligibility criteria (observational registry or randomization) 1. Prior history of head and neck cancer with no active disease. 2. Treated previously with radiotherapy with prescribed dose (greater or equal to 30Gy) to unilateral or bilateral neck(s) 3. Detectable CTC-AE G2+ lymphedema/fibrosis at \>6 months post-radiotherapy. 4. No active liver disease (Child-Pugh class B-C), cirrhosis, nor active alcoholism, nor history of ulcers. 5. No history of myopathy/rhabdomyolysis. 6. Creatinine clearance \<30mL/min. 7. No history of acute myocardial infarction or severe coronary disease. 8. Non-pregnant/post-menopausal, or male. 9. No history of diabetes mellitus 10. Allergy/hypersensitivity to HMG Co-A reductase inhibitor and/or xanthine derivatives, e.g., caffeine, theophylline, theobromine 11. No contraindications for magnetic resonance imaging a Subject to the discretion of the treating physician and Principal Investigator (PI), as the MRI may be optional Exclusion Criteria 1. Active liver disease (Child-Pugh class B-C), cirrhosis, nor active alcoholism. 2. History of myopathy/rhabdomyolysis. 3. History of acute myocardial infarction or severe coronary disease. 4. Pregnant/post-menopausal, or male. 5. History of diabetes mellitus. 6. Allergy/hypersensitivity to Hydroxymethylglutaryl-coenzyme A (HMG Co-A) reductase inhibitor and/or xanthine derivatives, e.g., caffeine, theophylline, theobromine. 7. Contraindications for MRI Subject to the discretion of the treating physician and Principal Investigator (PI), as the MRI may be optional 8. Participants who are receiving any other investigational agents. 9. History of allergic reactions attributed to compounds of similar chemical or biologic composition to statins, hemorheologic agents or other agents used in study 10. Participants with psychiatric illness/social situations that would limit compliance with study requirements.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Fibrosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Inhaled drug aims to ease dangerous lung blood pressure in scarred lungs
- Could gut bacteria predict infection risk in lymphedema?
- Could online therapy ease the swelling of breast cancer lymphedema?
- Ultrasound could uncover hidden vascular risks in turner syndrome
- Can swollen limbs throw off your balance? a study investigates
- Could reapplying compression bandages three times a day beat the standard Once-Daily treatment for lymphedema?